Brief: Longboard Pharmaceuticals Announces Positive Interim Results From The Open-Label Extension Of The Phase 1B/2A Pacific Study Evaluating Bexicaserin In Participants With Developmental And Epileptic Encephalopathies
10/06/2024 14:14
June 10 (Reuters) - Longboard Pharmaceuticals Inc
LBPH.O :
* LONGBOARD PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM
RESULTS
FROM THE OPEN-LABEL EXTENSION (OLE) OF THE PHASE 1B/2A PACIFIC
STUDY EVALUATING BEXICASERIN IN PARTICIPANTS WITH DEVELOPMENTAL
AND EPILEPTIC ENCEPHALOPATHIES (DEES)
* LONGBOARD PHARMACEUTICALS INC: FAVORABLE SAFETY AND
TOLERABILITY
RESULTS OBSERVED
Source text for Eikon: ID:nBw5HPRMMa
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions